Show simple item record

Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top‐Down” approach to intestinal fibrosis in mice

dc.contributor.authorJohnson, Laura A.en_US
dc.contributor.authorLuke, Amyen_US
dc.contributor.authorSauder, Kay L.en_US
dc.contributor.authorMoons, David S.en_US
dc.contributor.authorHorowitz, Jeffrey C.en_US
dc.contributor.authorHiggins, Peter D.R.en_US
dc.date.accessioned2012-03-16T16:00:57Z
dc.date.available2013-05-01T17:24:43Zen_US
dc.date.issued2012-03en_US
dc.identifier.citationJohnson, Laura A.; Luke, Amy; Sauder, Kay; Moons, David S.; Horowitz, Jeffrey C.; Higgins, Peter D.R. (2012). "Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top‐Down” approach to intestinal fibrosis in mice ." Inflammatory Bowel Diseases 18(3): 460-471. <http://hdl.handle.net/2027.42/90367>en_US
dc.identifier.issn1078-0998en_US
dc.identifier.issn1536-4844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90367
dc.description.abstractBackground: The natural history of Crohn's disease follows a path of progression from an inflammatory to a fibrostenosing disease, with most patients requiring surgical resection of fibrotic strictures. Potent antiinflammatory therapies reduce inflammation but do not appear to alter the natural history of intestinal fibrosis. The aim of this study was to determine the relationship between intestinal inflammation and fibrogenesis and the impact of a very early “top‐down” interventional approach on fibrosis in vivo. Methods: In this study we removed the inflammatory stimulus from the Salmonella typhimurium mouse model of intestinal fibrosis by eradicating the S. typhimurium infection with levofloxacin at sequential timepoints during the infection. We evaluated the effect of this elimination of the inflammatory stimulus on the natural history of inflammation and fibrosis as determined by gross pathology, histopathology, mRNA expression, and protein expression. Results: Fibrogenesis is preceded by inflammation. Delayed eradication of the inflammatory stimulus by antibiotic treatment represses inflammation without preventing fibrosis. Early intervention significantly ameliorates but does not completely prevent subsequent fibrosis. Conclusions: This study demonstrates that intestinal fibrosis develops despite removal of an inflammatory stimulus and elimination of inflammation. Early intervention ameliorates but does not abolish subsequent fibrosis, suggesting that fibrosis, once initiated, is self‐propagating, suggesting that a very early top‐down interventional approach may have the most impact on fibrostenosing disease. (Inflamm Bowel Dis 2012;)en_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherSalmonella Typhimuriumen_US
dc.subject.otherCrohn's Diseaseen_US
dc.subject.otherIntestinal Fibrosisen_US
dc.subject.otherColitisen_US
dc.subject.otherTop‐Down Interventional Approachen_US
dc.titleIntestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: Impact of a “Top‐Down” approach to intestinal fibrosis in miceen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Hospitals, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDivision of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Hospitals, Ann Arbor, Michiganen_US
dc.contributor.affiliationumDepartment of Pathology, University of Michigan Hospitals, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherSPC 5682, 1150 West Medical Center Dr., Ann Arbor, MI 48109en_US
dc.identifier.pmid21761511en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90367/1/21812_ftp.pdf
dc.identifier.doi10.1002/ibd.21812en_US
dc.identifier.sourceInflammatory Bowel Diseasesen_US
dc.identifier.citedreferenceBrand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009; 58: 1152 – 1167.en_US
dc.identifier.citedreferenceWirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007; 2: 541 – 546.en_US
dc.identifier.citedreferenceCosnes J. Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies? Dig Dis. 2009; 27: 516 – 521.en_US
dc.identifier.citedreferenceStrober W, Zhang F, Kitani A, et al. Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol. 2010; 26: 310 – 317.en_US
dc.identifier.citedreferenceHiggins PD, Johnson LA, Sauder K, et al. Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice. Comp Immunol Microbiol Infect Dis. 2011; 34: 247 – 257.en_US
dc.identifier.citedreferenceAndres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999; 28: 255 – 281, vii.en_US
dc.identifier.citedreferenceSands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003; 98: 2712 – 2718.en_US
dc.identifier.citedreferenceCosnes J, Cattan S, Blain A, et al. Long‐term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244 – 250.en_US
dc.identifier.citedreferenceFeagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000; 95: 1955 – 1960.en_US
dc.identifier.citedreferenceLichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol. 2006; 101: 1030 – 1038.en_US
dc.identifier.citedreferenceLouis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777 – 782.en_US
dc.identifier.citedreferenceGrassl GA, Valdez Y, Bergstrom KS, et al. Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology. 2008; 134: 768 – 780.en_US
dc.identifier.citedreferenceRieder F, Lawrance IC, Leite A, et al. Predictors of fibrostenotic Crohn's disease. Inflamm Bowel Dis. 2011 [Epub ahead of print].en_US
dc.identifier.citedreferenceSelman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001; 134: 136 – 151.en_US
dc.identifier.citedreferenceLin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn's disease: step‐up or top‐down? Expert Rev Gastroenterol Hepatol. 2010; 4: 167 – 180.en_US
dc.identifier.citedreferenceDomenech E, Manosa M, Cabre E. Top‐down therapy: is the evidence strong enough? Dig Dis. 2009; 27: 306 – 311.en_US
dc.identifier.citedreferenceHanauer SB. Medical management of Crohn's disease: treatment algorithms 2009. Dig Dis. 2009; 27: 536 – 541.en_US
dc.identifier.citedreferenceVermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease—evidence for and against current therapies. Aliment Pharmacol Ther. 2007; 25: 3 – 12.en_US
dc.identifier.citedreferencePeyrin‐Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33: 870 – 879.en_US
dc.identifier.citedreferenceJones DW, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg. 2010; 252: 307 – 312.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.